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Th17 cytokines induce pro-fibrotic cytokines
release from human eosinophils
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Abstract
Background: Subepithelial fibrosis is one of the most critical structural changes affecting bronchial airway function
during asthma. Eosinophils have been shown to contribute to the production of pro-fibrotic cytokines, TGF-β and
IL-11, however, the mechanism regulating this process is not fully understood.
Objective: In this report, we investigated whether cytokines associated with inflammation during asthma may
induce eosinophils to produce pro-fibrotic cytokines.
Methods: Eosinophils were isolated from peripheral blood of 10 asthmatics and 10 normal control subjects.
Eosinophils were stimulated with Th1, Th2 and Th17 cytokines and the production of TGF-β and IL-11 was
determined using real time PCR and ELISA assays.
Results: The basal expression levels of eosinophil derived TGF-β and IL-11 cytokines were comparable between
asthmatic and healthy individuals. Stimulating eosinophils with Th1 and Th2 cytokines did not induce expression of
pro-fibrotic cytokines. However, stimulating eosinophils with Th17 cytokines resulted in the enhancement of TGF-β
and IL-11 expression in asthmatic but not healthy individuals. This effect of IL-17 on eosinophils was dependent on
p38 MAPK activation as inhibiting the phosphorylation of p38 MAPK, but not other kinases, inhibited IL-17 induced
pro-fibrotic cytokine release.
Conclusions: Th17 cytokines might contribute to airway fibrosis during asthma by enhancing production of
eosinophil derived pro-fibrotic cytokines. Preventing the release of pro-fibrotic cytokines by blocking the effect of
Th17 cytokines on eosinophils may prove to be beneficial in controlling fibrosis for disorders with IL-17 driven
inflammation such as allergic and autoimmune diseases.
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Introduction
Asthma is a chronic inflammatory disorder of the lung
that is usually associated with airway tissue remodelling.
This term refers to the structural changes affecting
lung tissue which normally include epithelial detach-
ment, increased airway smooth muscle (ASM) mass,
subepithelial fibrosis, mucous gland and goblet cell hyper-
plasia, vascular changes, and edema [1-4]. Subepithelial
fibrosis is one of the most critical structural changes
associated with airway remodeling. In normal subjects, a
loose array of collagen fibrils resides beneath the basal
membrane. In asthmatics, however, this layer is replaced
by a dense network of extra-cellular matrix (ECM)
proteins including collagens [5]. ECM protein depo-
sition is known to be regulated by a number of cyto-
kines and growth factors including TGF-β [6]. Several
reports have shown that the majority of TGF-β1
mRNA positive cells in bronchial biopsies of severe
asthmatics were eosinophils [7-9]. Eosinophils were
also shown to produce IL-11 mRNA and protein [10].
These reports suggested that eosinophils could play
an important role in regulating tissue fibrosis. IL-5
deficient mice experiments [11] and human studies
[12] supported this hypothesis. In addition to lowe-
ring eosinophil levels, using anti-IL-5 antibodies was
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shown to be associated with reduced expression of ECM
proteins particularly tenascin, lumican, and procollagen
III [12].
Since its recent discovery, IL-17 has been described to
be involved in various aspects of asthma pathogenesis.
Elevated IL-17A levels were shown to correlate with in-
creased airway hyper-responsiveness (AHR) in asthmatics
[13]. In fact, IL-17 was shown to modulate airway struc-
tural cells leading to tissue remodeling. Over-expression of
IL-17 F resulted in goblet cell hyperplasia and mucin
gene expression [14]. In addition, using an in vitro
cell migration assay, Change et al. have recently
shown that Th17-associated cytokines IL-17A, IL-17 F,
and IL-22 promote migration of human ASMCs. These
effects were shown to be mediated by selective activation
of receptors on ASMCs, with IL-17A and IL-17 F acting
through p38 MAPK activation while IL-22 acting through
a distinct nuclear factor kB (NF-kB)–dependent signaling
pathway [15]. These studies indicated for a role of IL-17
in airway remodeling and hence in regulating asthma
pathogenesis.
Eosinophils have receptors for a number of mediators
that are associated with asthma including Th1, Th2, and
Th17 cytokines [16-18]. The expression of IL-17 cyto-
kines was also associated with subepithelial fibrosis
[19-21]. In fact, Th17 cytokines were shown to trigger
the expression of pro-fibrotic cytokines in bronchial
fibroblasts [22]. We, hence, hypothesized that IL-17
cytokines may induce eosinophils to produce pro-fibrotic
cytokines. In this paper, we stimulated eosinophils,
isolated from normal and asthmatic subjects, with
Th17 cytokines as well as a group of Th1 and Th2
cytokines known to be associated with asthma. Eosinophil
production of TGF-β and IL-11 pro-fibrotic cytokines was
then investigated.
Materials and methods
Study subjects
Ten subjects with severe asthma (6 males and 4 females,
mean age 33.3 ± 2.6) who met the criteria defined by
ATS on refractory asthma [23] were recruited. To be
classified as severe asthmatics, patients must have had
high-dose inhaled corticosteroid: Budesonide 160 μg/twice
a day (or equivalent) or daily anti-leukotriene for >50% of
the last year, and at least 1 other add-on therapy on daily
basis for the previous 12 months. They were also required
to have two of the following criteria: daily short-
acting β-agonist, persistent FEV1 <60% and FEV1/FVC
<75% predicted, 1 urgent visit or at least 3 steroid bursts in
the previous year, prompt deterioration with <25% steroid
dose reduction, or previous near-fatal asthma within the
last 3 years. Subject characteristics are summarized in
Table 1. Exclusion criteria included smoking history or any
other pulmonary diseases or co-existing medical conditions
such as cardiac and renal diseases and uncontrolled
hypertension. Ten normal control subjects (6 males
and 4 females, mean age: 38.2 ± 3.4) were also recruited.
All normal control subjects were non-smokers with
normal lung function, no history or symptoms of
allergy and respiratory diseases, and were not taking
any medications for the preceding four weeks. The
Ethics Committee of the King Khalid University Hospital
in Riyadh reviewed and approved the study, and all
subjects recruited signed written informed consent for
the drawing of peripheral venous blood for the isolation
of eosinophils.
Isolation and culture of eosinophils
Peripheral venous blood were drawn from patients with
severe asthma (120-180 ml) (60 ml every 3 months)
and from normal control subjects (180-240 ml) (60 ml
Table 1 Demography and spirometry data of the recruited subjects
Asthmatics Healthy controls
Age (years) 33.3 ± 2.6 38.2 ± 3.4
Males/females 6/4 6/4
Atopy (% of total) 100% 0
Duration of disease (years) 16.5 ± 9.8 n/a
Peripheral Blood Eosinophls 0.78 ± 0.04×109/l 0.31 ± 0.02×109/l
FEV1 (mean ± SD) 57.73 ± 2.56 107.5 ± 5.63
FVC (mean ± SD) 75.14 ±3.27 104.6 ± 6.87
FEV/FVC (mean ± SD) 66.34 ± 5.39 83 ± 4.62
Medications - Inhaled corticosteroids: Symbicort II (Budesonide/Formoterol)
(160/4.5 ug) (1–2 inhalations twice daily).
No
- Anti-leukotriene: Singulair (montelukast sodium) (10 mg/d).
- Ventolin (albuterol) (as needed).
Except for the medications indicated above, the patients were not receiving any other immunosupressive drugs. FEV1 forced expiratory volume; FVC forced
vital capacity.
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every 3 months). Eosinophils were isolated by negative
selection using MACS Isolation Kit (Miltenyi Biotec,
Auburn, CA, USA) as previously described [24].
Neutrophils, monocytes and T cells were labeled with
anti-CD16, anti-CD14 and anti-CD3 Abs respectively
bound to immunemagnetic beads and separated with
MACS LD Separation column. Eosinophil purity was
consistently >98% as evaluated by Hema3 (Fisher)
staining and the viability of freshly isolated eosino-
phils was >99% as evaluated by Trypan blue dye
exclusion. Isolated eosinophils were then cultured in
RPMI + 10% FCS in the presence of 30 pg/ml IL-5
cytokine required for eosinophil survival in vitro
[25,26]. Eosinophil viability ranged between 85 and
92% following stimulation and culture.
ELISA assay
Eosinophils (2×106 cells/ml cultured in 24 well plate) were
stimulated with Th1 (IL-2, IFN-γ) (50 ng/ml), Th2 (IL-4,
IL-5, IL-9, IL-13) (50 ng/ml), and Th17 (IL-17A, IL-17 F,
IL-23) (10, 25, 50, or 100 ng/ml) cytokines (R&D Systems,
Minneapolis, Minn., USA) for 24 hrs and supernatants
were collected. In some experiments, eosinophils were
treated with p38 mitogen-activated protein kinase
(MAPK) inhibitors (SB 203580; 5 μM, Invivogen San
Diego, CA, USA) or PI3K inhibitor (PI103; 5 μM, Cayman
Chemical, Ann Arbor, Mich., USA) 2 hours prior to stimu-
lation with IL-17. Levels of secreted TGF-β and IL-11 in
supernatants were determined using ELISA assay (R&D
Systems, Minneapolis, Minn., USA) according to the
manufacturer instructions.
RNA extraction and real-time RT-PCR
Eosinophils were stimulated with cytokines (Th1
(50 ng/ml), Th2 (50 ng/ml) or Th17 (50 ng/ml)) for
4 hours prior to cell harvest. In some experiments,
eosinophils were treated with p38 MAPK inhibitors
(SB 203580; 5 μM), or PI3K inhibitor (PI103; 5 μM) 2 hours
prior to stimulation with IL-17. Cells were then harvested,
total RNA extracted (levels of RNA extracted from 2×106
eosinophils were 18.4 ± 4.7 μg for asthmatic eosinophils
and 16.3 ± 3.9 μg for healthy controls) (RNeasy Mini kit,
Qiagen, CA, USA) and modulations of the level of
expression of TGF-β and IL-11 mRNA were determined
using quantitative RT-PCR (Applied Biosystems, 7900 Fast
RT-PCR system). Specific primers for TGF-β and IL-11
were as follows: TGF-β: Forward: 5-CTGGACACCCTAA
CCGTGAT-3, Reverse: 5-CTAGGCCGTGCTGCTGCT-3;
IL-11: Forward: 5-GTGGCCAGATACAGCTGTCGC-3,
Reverse: 5- GGTAGGACAGTAGGTCCGCTC-3. Relative
expressions of TGF-β and IL-11 genes normalized
with GAPDH were determined by the delta-delta Ct
method [27].
Assessment of p38 MAPK phosphorylation by western
analysis
2×106 eosinophil cells were starved using medium with
0.1% FBS for 18 hours. Cells were stimulated with
50 ng/mL IL-17A and IL-17 F for 0, 10, and 20 minutes
and total proteins were extracted using lysis buffer (1%
Triton X-100 containing protease and phosphatase inhibi-
tor cocktails (Roche, Mannheim, Germany). Protein lysates
(10 μg) were then resolved on 10% acrylamide SDS-
PAGE gel and blots were probed with antibodies to
phosphorylated p38 MAPK (Millipore) and total p38
MAPK (Millipore). Membranes were analyzed with an
Odyssey IR scanner using Odyssey imaging software 3.0
(LI-COR Biosciences, Inc).
Statistical analysis
Data are presented as mean ± SD. Expression of pro-
fibrotic cytokines was evaluated using ANOVA
followed by Bonferroni-Dunn post hoc test. Non-
parametric Mann–Whitney U test (Systat, version
7.0, SPSS, Chicago, IL) was used to evaluate significance in
differential phosphorylation of MAPK. Values of p < 0.05
were considered statistically significant.
Results
Th1 and Th2 cytokines do not induce expression of
eosinophil derived pro-fibrotic cytokines
The patho-physiological characteristics of lung tissue
inflammation during severe asthma differ significantly
from those of the milder disease. While the airway
tissues of mild asthmatics usually present preferential
Th2 cytokine profile [28], those from severe asthmatics
show a Th17 lymphocyte infiltration and elevated
cytokine levels, particularly Th1 cytokines (IFN-γ, IL-2),
IL-17 and TGF-β [29-31]. Many T-helper cytokines were
shown to play a significant role in regulating TGF-β
expression and function in different types of cells [32-34].
However, their direct role in regulating eosinophil ability to
produce pro-fibrotic cytokines was not studied. To investi-
gate that, we first determined the basal expression levels of
pro-fibrotic cytokines within peripheral blood eosinophils
of 10 asthmatic and non-asthmatic individuals using real
time RT-PCR. The levels of expression of TGF-β and IL-11
mRNA in eosinophils isolated from asthmatic individuals
(ct values: TGF-β: 27.53 ± 0.21 IL-11: 28.80 ± 1.2) were
comparable to those isolated from healthy controls
(ct values: TGF-β: 27.70 ± 0.29 IL-11: 29.56 ± 0.86)
(Figure 1A). Eosinophil supernatant IL-11 and TGF-β
cytokines levels were also determined in the two groups
using ELISA assay (Figure 1B). Similarly, no change in the
secreted levels of these pro-fibrotic cytokines was detected
between the two groups. We then investigated whether
Th1 and Th2 cytokines play a role in regulating eosino-
phils pro-fibrotic cytokines production. To do that, we
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Figure 1 (See legend on next page.)
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stimulated 2×106 eosinophil cells isolated from 10 asth-
matic as well as healthy individuals with Th1 (IL-2, IL-12,
and IFN-γ), and Th2 (IL-4, IL-5, IL-9, and IL-13) cytokines
as well as GM-CSF for 4 hrs. Total RNA was then
extracted from stimulated eosinophils and the level of IL-
11 and TGF-β was determined using real time RT-PCR. As
shown in Figure 1C-D, stimulating asthmatic eosinophils
with Th1 or Th2 cytokines did not affect TGF-β (ct values
range: 27.63 ± 0.21 to 27.58 ± 0.79) (Figure 1C) or IL-11
(ct values range: 28.67 ± 0.84 to 28.76 ± 0.18) (Figure 1D)
m-RNA levels. Similar results were obtained at higher
concentrations of Th1 and Th2 cytokines (100 ng/ml) as
well as for eosinophils isolated from healthy controls (data
not shown). These results indicated that neither Th1
nor Th2 cytokines play a significant role in regulating
expression of eosinophil derived pro-fibrotic cytokines.
Th17 cytokines enhance the expression of eosinophil
derived pro-fibrotic cytokines in asthmatic individuals
IL-17A enhanced the production of IL-6 and IL-11 in
bronchial fibroblasts [22] while IL-17 F was shown to
induce the expression of TGF-β in human umbilical vein
endothelial cells (HUVECs) [35]. IL-17A and IL-17 F
were recently shown to be over expressed in bronchial
lung tissue of asthmatic patients compared to healthy
controls [29] and their level of expression was associated
with the severity of the diseases. Interestingly, using
FACS and western analysis, eosinophils were also shown
to express receptors for Th17 cytokines [16]. We,
therefore, hypothesised that Th17 cytokines may induce
eosinophils to produce pro-fibrotic cytokines. To investi-
gate that, we first determined the expression levels of
IL-17R on eosinophils isolated from both groups. As in-
dicated in Figure 2A, eosinophils from both healthy and
asthmatic subjects express IL-17R. Although asthmatic
eosinophils express higher levels of IL-17R, this increase
did not reach significance. We next stimulated 2×106
eosinophils, isolated from 10 severe asthmatic patients
and 10 healthy controls, with IL-17A, IL17F, as well as
IL-23, another Th17 cytokine for 4 hrs. Total RNA was
then extracted and eosinophil expression of TGF-β and
IL-11 mRNA was measured using real-time PCR. As
shown in Figure 2B, contrary to stimulating eosinophils
with IL-17A and IL-17 F alone, stimulation with a com-
bination of IL-17A + F (ct value: 24.39 ± 0.17, P = 0.031;
n = 10), or IL-23 (ct value: 24.42 ± 0.21, P = 0.025; n = 10)
alone, induced a significant increase in the expression of
eosinophil derived TGF-β. Further increase in TGF-β ex-
pression was observed when stimulating with double
the amount of the combined cytokines IL-17A + F (ct
value: 24.06 ± 0.4, P = 0.012; n = 10) and or IL-17A +
F + IL-23 (ct values: 23.98 ± 0.16, P = 0.018; n = 10). Inter-
estingly, this increase in TGF-β production was only ob-
served within eosinophils isolated from asthmatic patients.
Stimulation of eosinophils isolated from non-asthmatic in-
dividuals with Th17 cytokines had no effect on TGF-β
production (ct values: IL-17A + F: 25.29 ± 0.15; IL-23:
25.22 ± 0.18; IL-17A + F (50 ng): 25.36 ± 0.14; IL-17A +
F + 23 (50 ng): 25.78 ± 0.11, p =NS) (Figure 2B). Similarly, a
combination of IL-17A and IL-17 F at different concentra-
tions or IL-17A + F + IL-23 induced a significant increase in
IL-11 mRNA expression within eosinophils isolated from
asthmatics (ct values: IL-17A + F (25 ng): 24.61 ± 0.37, p =
0.029; IL-17A + F (50 ng): 23.71 ± 0.70, p = 0.009; IL-
17A + F + 23 (50 ng): 23.80 ± 0.37, p = 0.014, n = 10)
but not healthy subjects (ct values: IL-17A + F
(25 ng): 25.18 ± 0.10; IL-17A + F (50 ng): 25.10 ± 0.11;
IL-17A + F + 23 (50 ng): 25.00 ± 0.13, p = NS) (Figure 2C).
To determine effective concentration inducing eosinophils
release of TGF-β and IL-11 cytokines, a dose response ef-
fect of Th17 cytokines was performed. Eosinophils were
treated with increasing concentration of Th17 cytokines
and levels of TGF-β and IL-11 in their supernatant
were determined using ELISA assay (Figure 3A). Al-
though low concentrations of Th17 cytokines in-
duced pro-fibrotic cytokine secretion, a significant
enhancement of TGF-β and IL-11 release was only
attained at 50 ng/ml and above. At this concentration, the
level of eosinophil derived TGF-β was significantly increa-
sed following treatment with a combination of IL-17A + F
(P = 0.032; n = 10), IL-23 (P = 0.049; n = 10) alone, or IL-
17A + F + IL-23 (P = 0.043; n = 10) (Figure 3A). Similarly,
IL-11 secreted levels were significantly upregulated
following stimulation with a combina- tion of IL-
17A + F (P = 0.035; n = 10), IL-23 (P = 0.048; n = 10)
alone, or IL-17A + F + IL-23 (P = 0.043; n = 10)
(Figure 3B). This data suggest that, in an asthmatic en-
vironment, an additive effect of Th17 cytokines en-
hance the production of eosinophils derived pro-fibrotic
cytokines.
(See figure on previous page.)
Figure 1 Basal expression of pro-fibrotic cytokines by human eosinophils isolated from asthmatic and controls subjects. Eosinophils
were isolated from 10 asthmatic and 10 controls subjects and total RNA was extracted from 2×106 million cells and quantified using real-time
PCR. A: Level of expression of TGF-β1 and IL-11 mRNA in eosinophils of asthmatic versus control subjects (n = 10). B: Levels of TGF-β1 and IL-11
cytokines within the supernatant of un-stimulated eosinophils (n = 10) as determined by ELISA assay. (C-D) Effect of Th1 and Th2 cytokines on
asthmatic eosinophil TGF-β1 and IL-11 transcripts levels. Level of expression of TGF-β1 (C) and IL-11 (D) mRNA as quantified by real-time PCR
following 4 hours exposure to mediators. Data is presented as percentage of basal expression (n = 10).
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IL-17 cytokine enhance eosinophil derived TGF-β and
IL-11 production through P38 MAP kinase activation
P38 mitogen-activated protein kinase (MAPK), being at
a critical junction of the IL-17 signaling pathways, has
been shown by various reports to be a key regulator
element for the activity of IL-17 cytokines [15,16,36]. To
study the mechanism behind Th17 cytokines enhance-
ment of eosinophil derived TGF-β production, eosino-
phils were isolated from peripheral blood of 10
asthmatic patients as described above. 2×106 cells were
treated, or not, with p38 MAPK or PI3K inhibitors
(SB2035802 and PI103, respectively), or diluent control
A
B Asthmatic 
Ex
pr
es
sio
n
 
of
 
TG
F-
β1
 
m
R
N
A
/G
A
PD
H
(F
ol
d 
In
cr
ea
se
)
Ex
pr
es
sio
n
 
of
 
IL
-
11
 
m
R
N
A
/G
A
PD
H
(F
ol
d 
In
cr
ea
se
)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
NT IL-17A IL-17F IL-23 IL-17A+F IL-17A+F+23
*
*
*
IL-17A+F
17A: 25ng/ml
17F: 25ng/ml
(50ng/ml) 17A: 50ng/ml
17F: 50ng/ml
IL-23: 50ng/ml
17A: 50ng/ml
17F: 50ng/ml
IL-23: 50ng/ml
0
0.5
1
1.5
2
2.5
3
3.5
NT IL-17A IL-17F IL-IL23 IL-17A+F IL-17A+F+23
Healthy
*
*
*
*
IL-17A+F
17A: 25ng/ml
17F: 25ng/ml
(50ng/ml)
C
0
20
40
60
80
100
Healthy Asthmatic
Asthmatic
%
 o
f t
ot
al
 e
os
in
op
hi
l 
IL-17R
Healthy
37.7 72.4
Figure 2 IL-17 and IL-23 enhance eosinophil expression of pro-fibrotic cytokines. (A) Surface expression of IL-17R on eosinophils (1×106 cells)
isolated from healthy and asthmatics was determined by flow cytometry. Blots are representative data for eosinophils isolated from one healthy control
and one asthmatic patient. The graph shows arithmetic mean ± SD of IL-17R positive eosinophils as percentage of total eosinophils (n = 5). 2×106
peripheral blood eosinophils isolated from 10 asthmatic and 10 controls subjects were stimulated with IL-17A, F, and IL-23 (50 ng/ml or 25 ng/ml)
alone or in combination for 4 hrs. Total RNA was extracted and mRNA levels of TGF-β and IL-11 were then quantified using real-time PCR. mRNA
expression levels of TGF-β (B) and IL-11 (C) were normalized with GAPDH for asthmatic versus healthy individuals.
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(DMSO) 2 hours prior to stimulation with IL-17. As shown
in Figure 4, inhibiting phosphorylation of p38 MAPK
significantly decreased the level of TGF-β (P = 0.011
(IL-17A + F); P = 0.015 (IL-17A + F + 23); n = 10) and
IL-11 (P = 0.021 (IL-17A + F); P = 0.026 (IL-17A + F + 23);
n = 10) secreted into eosinophil supernatants 24 hrs
following Th17 cytokine stimulation (Figure 4A, B). This
blocking effect was only specific to p38 MAPK as diluent
control or inhibitor of another kinase (PI3K) did not affect
the supernatant levels of TGF-β and IL-11 (P = NS;
n = 10). This data indicated that p38 MAPK activation is
critical for IL-17 induced eosinophil derived pro-fibrotic
cytokine production. To confirm p38 MAPK phosphory-
lation following treatment with IL-17 cytokines, 2×106
eosinophil cell were treated with IL-17A + F (50 ng/ml
each) for 0, 10 and 20 minutes and the level of p38 MAPK
phosphorylation was then determined using western
analysis. As shown in Figure 4C, stimulating eosi-
nophils with a combination of IL-17A and IL-17 F
resulted in phosphorylation of p38 MAPK which
seems to peak at 10 minutes (3.5 fold increase, p = 0.039).
Inhibiting p38 MAPK, PI3K, or ERK1/2, however, did not
interfere with the ability of IL-23 to stimulate eosinophil
to produce pro-fibrotic cytokines. This indicated that
IL-23 may use other mechanisms to stimulate pro-fibrotic
cytokine release that need to be further investigated.
Discussion
Eosinophils constitute a major source of TGF-β in asth-
matic lung tissue [7-9]. Reduction of lung eosinophilia
by anti–IL-5 therapy in humans [12] or genetic knock
down in mice [11] significantly reduced airway fibrosis
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Figure 3 Th17 cytokines enhance eosinophil production and release of pro-fibrotic cytokines. Levels of TGF-β (A) and IL-11 (B) in the
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and pulmonary TGF-β1 levels. Here, we show, for
the first time, that Th17 cytokines enhance eosino-
phil derived TGF-β and IL-11 production. This effect
of Th17 cytokines was prominent on eosinophils
isolated from asthmatics but not healthy subjects.
Our results clearly demonstrate that eosinophils con-
stitute an additional site of action for Th17 cytokines
in asthma supporting a role for IL-17 in regulating
fibrosis and airway remodeling.
Although Th2 (IL-4, IL-5, and IL-13) cytokines has
earlier been reported to regulate the expression of TGF-β1
by eosinophils [37,38], other studies had shown no effect
of these cytokines on TGF-β expression [39]. Our results
support the latest reports as we did not see any increase in
TGF-β or IL-11 mRNA or protein expression following
stimulation with Th2 cytokines. Similarly, Th1 cyto-
kines had no effect on eosinophil derived TGF-β
expression. In fact, IFN-γ was previously shown to
inhibit TGF-β production in human airway epithelial
cells which is in consistence with our findings [38].
The enhancement of eosinophil derived pro-fibrotic
cytokine release upon IL-17 cytokines stimulation was
only significant in eosinophils isolated from asthmatic
individuals. Although there was a slight upregulation of
TGF-β and IL-11 expression in eosinophils isolated from
healthy individuals upon IL-17 stimulation, this increase
did not reach significance. Peripheral blood eosino-
phils of asthmatic patients were shown to be primed
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Figure 4 P38 MAP Kinase activation is required for IL-17 enhancement of eosinophil derived pro-fibrotic cytokines. Eosinophils were
isolated from peripheral blood of 10 asthmatic patients and 2×106/ml cells were treated, or not, with p38 MAPK or PI3K inhibitors (SB2035802
and PI103, respectively) 2 hours prior to stimulation with IL-17 (50 ng/ml). Levels of TGF-β (A) and IL-11 (B) in the supernatant of stimulated
eosinophils were then determined 24 hrs following Th17 cytokine stimulation using ELISA assay (n = 10). (C) Induction of p38 MAPK
phosphorylation by a combination of IL-17A and IL-17 F (50 ng/ml each) is detected by western analysis. The western data shown represent one
of similar results from 4 independent experiments. * = p < 0.05 compared to non-stimulated (NS). ** = p < 0.05 compared to stimulated
not inhibited.
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compared to those of healthy subjects [40-42] which may
render them more susceptible to IL-17 effect. Our results
suggest that IL-17 cytokines enhance pro-fibrotic activity of
activated, such as in the case of allergic and auto-immune
diseases, but not resting eosinophils. Furthermore, our data
indicated that asthmatic eosinophils may express higher
levels of IL-17R than those of healthy controls (Figure 2A).
IL-23 was shown to increase expression of IL-17RA and
IL-17RC in eosinophils [16] and hence this observed poten-
tial increase in IL-17R in asthmatic eosinophils could be
due to increased serum IL-23 in those patients. Serum
levels of IL-23 were shown to inversely correlate with level
of pulmonary function (FEV1) of asthmatic patients in va-
rious reports [43,44]. This may indicate that, due to the
expected increase in serum IL-23 with asthma severity,
eosinophils isolated from mild and moderate asthmatic
patients may express higher levels of IL-17 receptors than
eosinophils of healthy controls but lower than those of
severe asthmatic patients. Understanding the correlation
between asthmatic patients’ IL-23 serum levels, the expres-
sion of IL-17R on peripheral blood eosinophils, and the
severity of asthma requires further investigations.
Eosinophils are known to produce IL-17 cytokines [22]
and IL-23 was shown to stimulate the expression of IL-17A
cytokine [45]. This may indicate that IL-23 could stimulate
eosinophils release of pro-fibrotic cytokines indirectly by
triggering their release of IL-17A. This possibility, however,
needs to be further investigated.
Stimulating eosinophils with IL-17 cytokines at a
physiologically relevant concentration (25 ng/ml) resulted
in an increase in TGF-β and IL-11 production although
not to a significant levels (Figure 3). While stimulating
eosinophils with either IL-17A or F alone did not enhance
a significant increase in pro-fibrotic cytokines, using a
combination of both cytokines did indicating an additive
effect. Since both IL-17A and IL-17 F share the same
IL-17R receptor [46], a concentration of around
25 ng/ml or more of each IL-17 cytokine seems to be
required for efficient eosinophil derived pro-fibrotic cyto-
kine release. This is more likely to be achieved in vivo
through the additive effect of IL-17A and F rather than a
high concentration of a single IL-17 cytokine alone.
Accumulating evidences from various reports indicate
for a key role of p38 MAPK pathway in IL-17 cytokine
activity on structural and inflammatory cells in asthma
[15,36]. Binding of IL-17A and F to the IL-17RA and RC
receptors on target cells triggers the recruitment of the
U-box E3 ubiquitin ligase Act1 (CIKS). Act1 will in turn
recruit TGF-β activated kinase that serves as the
template for the activation of the transcription factors
NF-kB, CEBPb (beta), as well as the MAPK pathways
ERK1/ERK2 and p38 MAPK [47]. P38 MAPK, ERK, and
JNK pathways were shown to regulate TGF-β transcrip-
tion each in response to different stimuli [48]. Our data
suggest that IL-17 cytokines stimulate TGF-β transcrip-
tion via the activation of p38 MAPK but not PI3K or
ERK1/2 MAPK (data not shown) pathways. IL-23,
however, seems to use another mechanism as inhibiting
those pathways did not affect its ability to stimulate
TGF-β and IL-11 production.
Conclusions
Data presented herein suggest a new role for Th17
cytokines in airway remodeling during asthma. IL-17
cytokines seem to contribute to airway tissue fibrosis by
enhancing production of eosinophil derived pro-fibrotic
cytokines. This role of IL-17 was dependent on p38
MAPK activation. Therefore, upstream activators of p38
MAPK within the IL-17R pathway may represent an
attractive target in corticosteroid-unresponsive diseases
[49,50]. Preventing the release of TGF-β by blocking the
effect of IL-17 on eosinophils may also prove efficient in
controlling fibrosis for disorders with IL-17 driven
inflammation such as allergic and autoimmune diseases.
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